LiqTech wins first commercial aquatics order in Finland for Helsinki hotel pool
Bitget2026/10/06 13:03LiqTech International received its first commercial aquatics order in Finland for the swimming pool at Original Sokos Hotel Presidentti in Helsinki. The order was secured through its Pool4You partnership, extending LiqTech’s commercial pool footprint into a new market. The Helsinki project specifies a 2 × 2 membrane configuration with AutoCIP for LiqTech’s QlariFlow aquatics filtration platform. LiqTech expects the installation to support its strategy to expand adoption of its silicon carbide membrane filtration systems in commercial pools. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LiqTech International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060900PRIMZONEFULLFEED9840054) on October 06, 2026, and is solely responsible for the information contained therein.
- LiqTech International received its first commercial aquatics order in Finland for the swimming pool at Original Sokos Hotel Presidentti in Helsinki.
- The order was secured through its Pool4You partnership, extending LiqTech’s commercial pool footprint into a new market.
- The Helsinki project specifies a 2 × 2 membrane configuration with AutoCIP for LiqTech’s QlariFlow aquatics filtration platform.
- LiqTech expects the installation to support its strategy to expand adoption of its silicon carbide membrane filtration systems in commercial pools.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.